Cipla Limited (“Cipla”), has said that it has received final approval for its Abbreviated New Drug Application (ANDA) for Isoproterenol Hydrochloride Injection USP, 0.2mg/mL, single - use sterile Ampoule from the United States Food and Drug Administration (US FDA ).
Cipla’s Isoproterenol Hydrochloride Injection USP, 0.2mg/mL, ampoule is AP - rated generic therapeutic equivalent version of Hospira Inc’s Isuprel ® Injection, 0.2mg/m.
According to IQVIA (IMS Health), Isuprel Injection and its generic equivalents had US sales of approximately USD 1 48 M for the 12-month period ending April 2018.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
Meanwhile, shares of the company were trading at Rs 589.30 apiece up 1.36 per cent from the previous close at 09:28 hrs on BSE.